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Abstract
Fibroproliferative disorders include neoplastic and reactive processes (e.g. desmoid tumor and hypertrophic scars). They are
characterized by activation of b-catenin signaling, and effective pharmacologic approaches are lacking. Here we undertook
a high throughput screen using human desmoid tumor cell cultures to identify agents that would inhibit cell viability in
tumor cells but not normal fibroblasts. Agents were then tested in additional cell cultures for an effect on cell proliferation,
apoptosis, and b-catenin protein level. Ultimately they were tested in Apc1638N mice, which develop desmoid tumors, as
well as in wild type mice subjected to full thickness skin wounds. The screen identified Neofopam, as an agent that inhibited
cell numbers to 42% of baseline in cell cultures from b-catenin driven fibroproliferative disorders. Nefopam decreased cell
proliferation and b-catenin protein level to 50% of baseline in these same cell cultures. The half maximal effective
concentration in-vitro was 0.5 uM and there was a plateau in the effect after 48 hours of treatment. Nefopam caused a 45%
decline in tumor number, 33% decline in tumor volume, and a 40% decline in scar size when tested in mice. There was also
a 50% decline in b-catenin level in-vivo. Nefopam targets b-catenin protein level in mesenchymal cells in-vitro and in-vivo,
and may be an effective therapy for neoplastic and reactive processes driven by b-catenin mediated signaling.
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Introduction
b-catenin plays a critical role in mesenchymal cell function,
regulating cell proliferation, motility, and differentiation. Muta-
tions which stabilize its protein level can cause the mesenchymal
tumor aggressive fibromatosis [1]; its level of activity regulates scar
size in wound healing [2]; and it regulates mesenchymal cell
differentiation during some reparative processes such as fracture
repair [3]. b-catenin is a central mediator in the canonical Wnt
pathway, whose activation is initiated by the binding of an
appropriate Wnt ligand to the Frizzled and low-density lipoprotein
receptor related protein co-receptor complex. In the absence of an
appropriate Wnt ligand, b-catenin is phosphorylated at amino
terminal serine and threonine sites, resulting in its being targeted
for ubiquitination and proteosomal degradation by a multi-protein
complex comprising glycogen synthase kinase-3b (GSK-3b),
Adenomatous Polyposis Coli (APC), and Axin. In the presence
of an appropriate Wnt ligand, this multiprotein complex does not
target b-catenin for degradation. b-catenin translocates to the
nucleus, where in concert with members of the T-cell-factor/
Lymphoid-enhancer-factor (Tcf/Lef) family, regulates transcrip-
tion in a cell type specific manner [4].
Cutaneous wound healing reestablishes the barrier and
mechanical properties of skin, and progresses through overlapping
inflammatory, proliferative, and remodeling phases. During the
proliferative phase of wound repair, mesenchymal cells accumu-
late to reestablish the mechanical properties of the injured tissue.
These cells are also responsible for the size of the scar that
ultimately forms [5,6]. Data from genetically modified mice in
which b-catenin level regulates scar size, and from observations in
patients in which hypertrophic scars are associated with high levels
of b-catenin [3], show that b-catenin regulates the number of
mesenchymal cells that accumulate during the proliferative phase
of wound repair and ultimately scar size [2,7,8,9,10]. Disordered
would repair, such as occurs in hypertrophic scars, lead to loss of
function (e.g. limited joint motion) and have major psychosocial
implications (e.g. disfigurement) [11], resulting in significant health
problems [6,12].
Aggressive fibromatosis (also called desmoid tumor) is a locally
invasive soft tissue tumor comprised of mesenchymal fibroblast-
like spindle cells [13]. It occurs as either a sporadic lesion or a
familial syndrome, such as familial infiltrating fibromatosis, or
familial adenomatous polyposis [14]. b-catenin stabilization is a
universal occurrence in aggressive fibromatosis, and in most cases
it is caused by a somatic mutation in b-catenin removing an amino
terminal serine or threonine phosphorylation site, although in
familial cases it is associated with a germline mutation in APC
[15,16,17]. b-catenin stabilization is sufficient to cause aggressive
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expresses a stabilized form of b-catenin [9]. Aggressive fibroma-
tosis is problematic to treat, with recurrence frequently occurring
after chemotherapy or surgery. Because of the cytologic similarity
to hypertrophic scarring and a role for b-catenin in both processes,
aggressive fibromatosis is sometimes thought of as unchecked
wound repair [18].
There are no universally effective pharmacologic approaches to
manage these b-catenin driven fibroproliferative disorders. One
strategy to identify an effective pharmacologic treatment is to
examine libraries of diverse compounds for a potentially effica-
cious agent. Libraries of such compounds in which pharmacoki-
netic and toxicologic data is already available, makes the
translation to patient care potentially easier [19]. Here we report
on the use of this screening approach to identify a compound that
targets cell viability driven by b-catenin in mesenchymal cells, and
tested its ability to decrease scar size in cutaneous wound repair
and as a therapeutic approach for the tumor, aggressive
fibromatosis.
Results
A compound screen identified Nefopam as an agent that
inhibits viability in cell cultures from aggressive
fibromatosis and hypertrophic cutaneous wounds
To identify potential agents that could be used to target
mesenchymal cells in which b-catenin is activated, we examined
primary cell cultures from aggressive fibromatosis and normal
fibroblast cultures from the same patients, as well as from primary
fibroblast cell cultures from hypertrophic scars and normal
fibroblasts from the same patients. Cell cultures were prepared
as previously reported [8,16]. The cultures were screened using
the MicroSource Spectrum collection, which consists of 2,000
compounds, some of which are already in use in humans [20].
Compounds were selected for further study based on two criteria:
that they inhibited cell viability in cell cultures obtained from
aggressive fibromatosis tumors; and that they showed little to no
effect on normal fibroblast cell cultures from the same patient. The
experiments were repeated in triplicate within 96 well plates, with
each well containing 4000 cells treated with 0.1 1.0, or 10 mMo f
each compound or DMSO as a control and studies after three
days in culture. The Sulforhodamine B assay (SRB) was used to
measure cell viability, and a robotic system used to measure
relative viability in each well. Compounds identified in the initial
screen underwent further testing using six additional aggressive
fibromatosis samples primary fibroblast cell cultures from hyper-
trophic scars from six patients. In all twelve cases normal
fibroblasts from the same patients were also studied. The agent
was tested at a variety of doses, and for various durations ranging
from one to four days. This screening process identified the agent,
5-methyl-1-phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine, or Ne-
fopam [21], which met the criteria in that it inhibited cell viability
in cultures derived from hypertrophic wound samples and
aggressive fibromatosis cell cultures, but not in normal fibroblasts
from the same patients (Fig. 1).
Nefopam inhibits cell proliferation in fibroblast cell
cultures from aggressive fibromatosis tumors and from
hypertrophic cutaneous wounds
Cell cultures from hypertrophic cutaneous wounds and from
aggressive fibromatosis tumors, along with normal fibroblasts from
the same patients, were then examined for the effect of Nefopam
on cell proliferation, and apoptosis after two days in culture. Cells
from aggressive fibromatosis tumors or hypertrophic wounds
treated with Nefopam had a significantly lower proliferation rate,
while normal fibroblasts from the same patients did not
demonstrate an appreciable change in proliferation rate, as
measured using the BrdU incorporation assay [22] (Fig. 2A).
There was a modest, but not significant change in apoptosis, as
detected using annexin V staining [23] (Fig. 2B). Cell cultures were
also treated with diphenhydramine, as a structural control since
Nefopam is derived from this compound [24]. Diphenhydramine
treatment had no effect on any of the cell parameters tested. The
half maximal effective concentration (EC50) for Nefopam was
0.5 uM and there was a plateau in the effect after two days
(48 hours) of treatment. Thus, Nefopam has predominant effect
inhibiting cell proliferation, in these cell cultures.
Nefopam reduces b-catenin protein level
To examine whether Nefopam has the capacity to modulate b-
catenin, we studied primary cell cultures derived from aggressive
fibromatosis tumors, hypertrophic wound fibroblasts, as well as
normal fibroblasts from the same patients. Western blot analysis
using an antibody against total b-catenin demonstrated a marked
decrease in the amount of protein as a result of Nefopam
treatment (Fig. 3A). To determine if Nefopam inhibits canonical
Wnt signaling, we treated normal fibroblasts with Wnt3a and
examined the level of b-catenin level, as well as the phosphory-
lation level of another canonical Wnt mediator, GSK3-b, with and
without treatment with Nefopam. There was a significant increase
in the level of serine-9-phosphorylation of GSK-3-b and b-catenin
with Wnt3a treatment. Nefopam treatment inhibited the levels of
serine-9-phospho-GSK-3-b and b-catenin back towards baseline
levels when the cells were treated with Wnt3a (Fig. 3B), showing
that the Nefopam targets canonical Wnt signaling cascade in
fibroblasts. To determine if Nefopam affects cells expressing a
mutant form of b-catenin, we examined fibroblasts expressing a
form of b-catenin lacking exon three [2], which encodes the amino
terminal serine or threonine phosphorylation sites. Treatment with
Nefopam resulted in a decrease in b-catenin protein level (Fig. 3C).
In all of the cultures examined, Nefopam did not alter the
expression of b-catenin at the mRNA level.
Nefopam suppresses the neoplastic phenotype in murine
aggressive fibromatosis tumors
We then investigated whether Nefopam treatment was able to
modulate the phenotype of aggressive fibromatosis tumors in vivo
using the Apc1638N mouse, which develops large numbers of
aggressive fibromatosis tumors [25]. The number of tumors that
developed in male mice treated with Nefopam was significantly
reduced compared to the number formed in mice provided with
no treatment or treated with 0.1% DMSO as vehicle or carrier
control at 5 months of age (Fig. 4). There was also a 25% decrease
in tumor volume.
Nefopam regulates scar size and b-catenin levels in
cutaneous wound repair
To examine if nefopam alters the phenotype in cutaneous
repair, we examined mouse skin wound healing. 4 mm full
thickness circular wounds were generated on the dorsal skin [2,9].
Nefopam or control was administered daily after wounding. Scar
size was determined using histologic observations of sections cut
across the wound perpendicular to the skin. The section with the
widest diameter of each scar was used to measure the relative scar
size, as previously reported [2]. 14 days after wounding, mice
treated with Nefopam had a scar diameter half that of control mice
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the effect of agents that cause hypertrophic scars, we examined if
Nefopam would reduce the large scar size due to subcutaneous
injection of TGF-b at the time of wounding. Nefopam treatment
of wounds treated with TGF-b resulted in a scar size close to that
of control wounds (Fig. 5A, C, E). Protein lysates extracted from
the scars were assayed for b-catenin levels. b-catenin levels are
higher in wounds treated with TGF-b. There was a significant
decline in b-catenin levels in the wound from mice treated with
Nefopam, compared to controls (Fig. 5F).
Figure 1. Nefopam inhibits cell viability in cultures from aggressive fibromatosis and hypertrophic cutaneous wounds. Data from the
Sulforhodamine B assay. The mean value for the cell culture treated with carrier was arbitrarily defined as 100 for each cell type. A) Data for a dose of
10 mM of Nefopam. There was a significantly lower level of cell viability in the aggressive fibromatosis or the hypertrophic scar cultures compared to
that seen in normal tissues. B) Data from different doses of Nefopam in cell cultures from aggressive fibromatosis or from hypertrophic scars, showing
a dose dependent decrease in cell viability. C) Time course data for cell viability after days of treatment with 10 mM of Nefopam in cell cultures from
aggressive fibromatosis or from hypertrophic scars. Data is given as means and 95% confidence intervals. Control data is generated by treatment with
diphenhydramine. Treatment with carrier alone gave identical results as for diphenhydramine. An asterisk over a data point indicates a significant
difference form the control cell cultures.
doi:10.1371/journal.pone.0037940.g001
Figure 2. Nefopam inhibits cell proliferation in fibroblast cell cultures from hypertrophic cutaneous wounds and from aggressive
fibromatosis tumors. Percent BrdU incorporation or annexin V staining from the various cell cultures treated with 10 mM of Nefopam. Data is given
as means and 95% confidence intervals. An asterisk over a data point indicates a significant difference form the control cell cultures. There was a
significant difference in BrdU incorporation in the tumor and hyperplastic scar cultures treated with Nefopam compared to treatment with carrier
alone. Treatment with diphenhydramine resulted in the identical findings as for treatment with the carrier.
doi:10.1371/journal.pone.0037940.g002
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Here we used a high throughput screen to identity Nefopam as
an agent that inhibits cell viability in mesenchymal cells in which
b-catenin is activated. To test this for its effects in-vivo, we
examined the mesenchymal tumor, aggressive fibromatosis, and
cutaneous wound repair in mice. Nefopam suppressed the
neoplastic phenotype in aggressive fibromatosis, and reduced the
scar size in wound healing.
Nefopam is a centrally-acting but non-opioid analgesic drug of
the benzoxazocine chemical class which was developed in the
1970s [26]. It was generated by cyclization of diphenhydramine
[24]. It has an analgesic effect is stronger than aspirin, but not as
strong as codeine, and has few side effects, especially as compared
to opioid analgesic agents [27]. The mechanism of action of
Nefopam is not completely elucidated, although inhibition of
serotonin, regulation of dopamine and noradrenaline reuptake,
and the regulation histamine H3 receptors and glutamate are all
hypothesized to play a role in its analgesic effect [28,29,30]. It also
acts as a voltage-gated sodium channel blocker, and this could
mediate its antinociceptive effects [31].
Despite what is known about the potential mechanism by which
Nefopam inhibits pain, the mechanism by which it inhibits b-
catenin signaling and suppresses fibroblast cell proliferation is not
clear. Since we found that the agent primarily influences cell
behavior when b-catenin is activated above physiologic levels, this
suggests a threshold effect. Such a threshold effect has been
demonstrated for some G-protein-coupled receptors, where the
intracellular proteins binding to a receptor will cause desensitiza-
tion when present above a certain threshold level [32]. D(2)-class
dopamine receptors exhibit such a G-protein-coupled desensitizing
effect, and can also regulate glycogen synthase kinase 3 activity
[33]. Since nefopam may regulate dopamine signaling, such an
effect could explain the mechanism by which nefopam regulates b-
catenin activity. While such a desensitizing mechanism is reported
to cause a threshold effect of a drug primarily when a signaling
pathway is activated, it is also possible that activation of a signaling
could inhibit expression of a protein that could bind a G-coupled
receptor. In this case signaling activation would decrease
expression of such a protein and thus cause desensitization of a
G-protein-coupled receptor. While such a mechanism is only
conjecture, a similar process can play a role in other instances,
such as in diabetes, where certain drugs will only have an effect in
diabetic rodents [34].
Our data shows that this agent can suppress the effects of high
levels of b-catenin due to activation by a Wnt ligand, a growth
factor known to activate b-catenin mediated transcription, and an
oncogenic mutation in b-catenin itself. Thus, it has a broad range
of activity suppressing the effects of b-catenin in mesenchymal
cells. It has a predominant effect in cell cultures modulating cell
proliferation, and this may be mediated by the decline in b-catenin
protein level, as activation of b-catenin mediated signaling
stimulates fibroblast proliferation [35]. Intriguingly, Nefopam
has little effect on b-catenin in normal fibroblasts, and this finding
raises the possibility that the agent primarily targets cells in which
b-catenin is activated above normal physiologic levels. Such a
characteristic makes Nefopam an enticing therapeutic agent, as it
suggests that it will have little effect on normal mesenchymal cells.
We found that nefopam primarily effects cell proliferation,
having little effect on apoptosis. This results in a relative decrease
in number of cells present in culture with nefopam treatment.
Since the Sulforhodamine B assay measures cell viability by
Figure 3. Nefopam modulates b-catenin protein level. A) Western blot analysis for b-catenin in aggressive fibromatosis and hypertrophic scar
cell cultures treated with Nefopam. A representative Western blot for total b-catenin is shown at the top of the panel. The data is shown in graphical
form in the lower part of the panel, as mean and 95% confidence intervals for the relative density compared to the loading control for six pairs of
cultures for each condition. An asterisk over a data point indicates a significant difference form the control cell cultures. There is a decrease in b-
catenin level with Nefopam treatment in cell cultures from both conditions. B) A representative Western blot for b-catenin and serine-9-phosph-GSK-
3-b in normal fibroblasts treated with Wnt3a is shown at the top of the panel. Composite data is shown in graphical form in the lower part of the
panel. Actin and total GSK3-b are used as loading controls. There is an increase in serine-9-phosph-GSK-3-b and b-catenin with Wnt3a treatment,
which is significantly lowered, close to the baseline level, with Nefopam treatment. C) A representative Western blot for b-catenin in fibroblasts
expressing a stabilized form of b-catenin lacking exon three is shown on the top of the panel. Composite data is shown in graphical form on the
bottom of the panel. There is a decrease in b-catenin with Nefopam treatment.
doi:10.1371/journal.pone.0037940.g003
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lower number of viable cells, despite no change in cell death. In
fibroproliferative processes, such an inhibition in cell proliferation
would limit the size of the associated fibrous, thus inhibiting tumor
growth and decreasing scar size.
b-catenin plays a role in a wide variety of neoplastic processes
[36,37], as well as in other non-neoplastic fibroproliferative
processes [18,38], such as renal fibrosis [39], pulmonary fibrosis
[40], skin fibrosis, [40] and palmar fibrosis (or Dupuytren disease)
[41]. This raises the possibility that Nefopam, would have a
therapeutic application in a wide variety of fibroproliferative and
neoplastic conditions. Indeed, blockade of b-catenin inhibit fibrosis
in some of these processes [42,43]. Thus, Nefopam could play a
therapeutic role in a broader range of conditions than the two
investigated in this study.
There is a lack of pharmacologic agents which target b-catenin
that can be readily used in patient care. Nefopam is an enticing
agent for use for this purpose as it has already been used in
patients, and found to have a strong safety record. As such, it has
the capacity to be rapidly brought to patient care to aid in the




This study was carried out in strict accordance with the
recommendations of the Canadian Council on Animal Care. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Toronto Centre for Phenogenemic and the
Hospital for Sick Children. The use of human material was
approved by the Institutional Review Board of the Hospital for
Sick Children. Written informed consent was obtained for the use
of the material.
Human cell cultures
Aggressive fibromatosis tumors were obtained at the time of
surgery. Tumor tissue and surrounding normal fascial tissue from
the same patient were processed immediately after surgical
excision, and primary cell cultures generated [17,44]. Hypertro-
phic wound samples and dermal fibroblasts from surrounding
normal skin were harvested at the time of surgery to revise the
scar, and primary cell cultures were prepared as reported [8].
Monolayer cultures were cultured in DMEM supplemented with
5% fetal bovine serum and maintained at 37uC in 5% CO2. Cells
were divided when confluent and experiments were performed
between the first and fourth passages. The details about the
patients, processing of tissues to generate primary cell cultures, and
maintenance of the cells in cultures is provided in previous
publications [8,17,44].
To identify potential agents that would target cell viability in
aggressive fibromatosis, we screened the MicroSource Spectrum
collection library (Discovery Systems, Inc. Gaylordsville, CT,
U.S.A.) which contains 2,000 agents, for compounds which meet
two criteria: 1) inhibit cell viability of fibroblasts obtained from
aggressive fibromatosis; and 2) show little to no effect on normal
fibroblast cultures. The experiments were repeated in triplicate
within 96 well plates, with each well containing 4000 cells treated
with between 0.1 1.0, or 10 mM of each compound or DMSO as a
control. The Sulforhodamine B assay (SRB) [45] was used to
measure cell viability. Data on Nefopam was verified using
additional cell cultures. Controls included the use of a carrier or
the use of a structural control, diphenhydramine from which
Nefopam is derived [24]. For these experiments hypertrophic
wound or aggressive fibromatosis cell cultures from additional
patients were studied. Normal fibroblasts as well as the pathologic
cells from each patient were tested. Cells were treated with vehicle
control 0.1% DMSO with or without Nefopam (Meda Pharma-
ceuticals, Bishop’s Stortford, UK) or diphenhydramine (Sigma-
Aldrich, Oakville, Ontario, Canada) prepared each used at the
same concentrations. Normal fibroblast cultures were also
examined with recombinant Wnt3a [46,47] (R and D systems,
Minneapolis, MN, U.S.A.) to activate the canonical Wnt signaling
pathway.
Proliferation was measured using 5-bromo-2-deoxy-uridine
(BrdU) Incorporation assay. After BrdU incubation for 12 hours,
cells with incorporated BrdU were identified using rabbit
monoclonal anti-BrdU antibody and horse anti-mouse antibody
conjugated to Alkaline Phosphatase. Presence of BrdU was
detected using Alkaline Phosphatase substrate. Percentage of
positively stained nuclei out of total nuclei was analyzed over 10
high-powered fields. Apoptosis was measured by annexin V
staining [23] using flow cytometry to detect positively stained cells.
Protein Analysis
Tissue samples or cells were treated with Lysis Buffer (Roche,
Montreal, Quebec, Canada). Equal quantities of total protein were
Figure 4. Nefopam suppresses the neoplastic phenotype in
murine aggressive fibromatosis tumors. The number of tumors
found in male Apc1638N mice. Data is given as the mean and 95%
confidence intervals for the number of tumors formed in male mice in
no treatment; 0.1% DMSO (carrier); or Nefopam treatment groups. Data
is given as means and 95% confidence intervals. An asterisk over a data
point indicates a significant difference form the control cell cultures.
Mice treated with the carrier showed a comparable number of tumors
to mice that received no treatment, while mice treated with Nefopam
developed significantly fewer tumors.
doi:10.1371/journal.pone.0037940.g004
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transferred to a nitrocellulose membrane, and immunoblotted
overnight at 4uC with primary antibodies against phospho-GSK3-
b (Ser 9, rabbit polyclonal, New England Biolabs, Pickering,
Ontario, Canada), b-catenin (mouse monoclonal, Upstate Bio-
technology, Lake Placid, NY, U.S.A.) total GSK3b (mouse
monoclonal, Transduction Laboratories, Mississauga, Ontario,
Canada), or GAPDH (mouse monoclonal, Upstate Biotechnology,
Lake Placid, NY, U.S.A.). Horseradish Peroxidase-tagged second-
ary antibodies and Enhanced ChemiLuminescence (Amersham,
Piscataway, New Jersey, U.S.A.) were used to detect hybridization.
Densitometery was performed using the AlphaEaseFC software
(Alpha Innotech, San Leandro, California, U.S.A.). Western
blotting was performed in triplicates to ensure reproducibility.
Mouse studies
Mice heterozygous for the Apc1638N allele harbor a targeted
mutation at codon 1638 of the Apc gene. Male mice develop as
many as 45 aggressive fibromatosis lesions by the age of 6 months,
but female mice develop fewer numbers of tumors than male mice
develop. Testosterone levels influence the sex difference in tumor
incidence [48]. These mice develop an average of six gastrointes-
tinal polyps at the same age. Male Apc1638N mice were divided
into three groups: No Treatment; carrier (0.1% DMSO); or
Nefopam (40 mg/kg body weight [49]). There were ten mice in
each group. Nefopan or carrier were administered daily by oral
gavages, starting at 2 months of age. Treatment was continued
until the mice were five months of age. At autopsy, an observer
blinded to the treatment regimen scored the size and number of
aggressive fibromatosis tumors and gastrointestinal polyps as
previously reported [50].
For wound healing experiments, two 4 mm diameter circular
full-thickness skin wounds were generated using a dermal biopsy
punch (Miltex Instrument Company, York, Pennsylvania, U.S.A.)
in wild type mice. Wounded mice were either treated with
Nefopam, 40 mg/kg body weight [49] given daily via oral
gavages, or a carrier group (10 mice in each group). At 14 days,
the mice were sacrificed, and wound tissues were collected for
histological examination. Scar size was measured from the
histologic sections as previously reported [2], using trichrome
stained sections cut across the wound perpendicular to the skin.
Serial sections were cut across the scar to identify the widest
diameter of each scar (mid aspect of the scar), and this section was
used to measure scar size. An observer blinded to the treatment
measured the scar size. An additional 16 mice were also treated
with TGF-ß at the time of wounding as previously reported [2,10],
and then with either Nefopam or carrier. The wounds were
examined 14 days following injury in an identical manner as for
the studies using nefopam alone. The scar size was averaged
between the two wounds in each mouse, and taken as a single
value for each mouse for statistical analysis. Primary cell cultures
were established from The Catnb
tm1Tak mouse, which possesses
loxP sites flanking exon 3 of the gene encoding for b-catenin.
When exposed to Cre-recombinase, this results in the conditional
stabilization of b-catenin. An adenovirus that expresses Cre-
recombinase was used to induce recombination, which was
verified using PCR and Western analysis. The details of the
Figure 5. Nefopam regulates scar size and b-catenin level in cutaneous wound repair. A to D) Representative histologic sections through
the widest margin of scars 14 days after wounding. A) A wound from a mouse treated with TGF-b. B) A wound in a mice treated with carrier only. C) A
wound from a mouse treated with TGF-b and Nefopam. D) A wound from a mouse treated with Nefopam. Arrows show the widest width of the scar.
The black line is 500 mm in length. E) A graphical representation of the mean and 95% confidence intervals of the widest diameter of the scars in mms.
F) A representative Western blot mice showing the b-catenin protein levels in wounds from mice treated with TGF-b, Nefopam, or both, showing that
Nefopam decreases b-catenin protein level in the wounds.
doi:10.1371/journal.pone.0037940.g005
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[2].
For mice treated with Nefopam, high-performance liquid
chromatography was performed on serum from the mice at the
time of sacrifice, using techniques as previously reported [51], to
verify systemic uptake of Nefopam.
Statistical analysis
Data in given as means 695% confidence intervals. Means and
standard deviations were compared using the t-test. The studies
were performed in at least triplicate.
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